{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:45:05Z","timestamp":1773413105219,"version":"3.50.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Invasive fungal infections are responsible for significant morbidity and mortality. Safety and effectiveness of antifungal agents is a particular concern in pediatric populations, where data are often limited. Micafungin is an echinocandin with demonstrated antifungal activity against a wide spectrum of <jats:italic toggle=\"yes\">Candida<\/jats:italic> spp.; this subanalysis of data from the MYRIADE study describes the use of micafungin and its therapeutic outcomes in pediatric patients, in normal clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>MYRIADE was an observational, multicenter, national, prospective, longitudinal study conducted from January 2010 to December 2012, in patients treated with micafungin using a prophylactic or curative strategy, across 17 sites [oncohematology (n = 8), neonatal intensive care units (ICUs) (n = 5) and pediatric ICUs (n = 4)]. The treatment regimen, the achievement of the therapeutic objective and the tolerance were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The study population consisted of 110 pediatric patients (31 neonates, 24 children &lt;2 years old and 55 children \u22652 to &lt;16 years old). The therapeutic objective was achieved in 49\/64 (76.6%) oncohematology patients, 28\/29 (96.6%) neonatal ICU patients and 12\/14 (85.7%) pediatric ICU patients. Twenty-four (21.8%) children developed an adverse event (AE); more AEs were observed in oncohematology patients compared with ICU patients [17 (26.1%) vs. 7 (15.6%)]. Only one serious AE, reported in an oncohematology patient, was considered related to micafungin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In the first large observational study of micafungin treatment or prophylaxis conducted under real-world conditions in France, micafungin was effective and well tolerated for prophylaxis of invasive fungal infections in pediatric oncohematology patients and for curative purposes in pediatric and neonatal ICU patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002353","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T09:02:25Z","timestamp":1560416545000},"page":"716-721","source":"Crossref","is-referenced-by-count":14,"title":["Use of Micafungin for the Prevention and Treatment of Invasive Fungal Infections in Everyday Pediatric Care in France: Results of the MYRIADE Study"],"prefix":"10.1097","volume":"38","author":[{"given":"Guy","family":"Leverger","sequence":"first","affiliation":[{"name":"Assistance Publique des H\u00f4pitaux de Paris, Pediatric Hematology Oncology Unit, Armand Trousseau Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[{"name":"Assistance Publique des H\u00f4pitaux de Paris, Medical and Infectious Diseases Intensive Care Unit, Bichat Hospital, Paris"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00ebl","family":"Milpied","sequence":"additional","affiliation":[{"name":"Hematology Department, Haut-Lev\u00e8que Hospital, Bordeaux"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Gachot","sequence":"additional","affiliation":[{"name":"Department of Acute Care, Gustave-Roussy Institute\u2014Cancer Campus Grand Paris, Villejuif, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3109\/1040841X.2014.974500","article-title":"Novel strategies to fight Candida species infection.","volume":"42","author":"Rodrigues","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.diagmicrobio.2005.03.002","article-title":"Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children\u2019s hospitals.","volume":"52","author":"Zaoutis","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12879-014-0725-7","article-title":"Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.","volume":"14","author":"Viscoli","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/myc.12268","article-title":"Invasive candidiasis and candidaemia in neonates and children: update on current guidelines.","volume":"58","author":"Tragiannidis","year":"2015","journal-title":"Mycoses"},{"key":"R5-20230912","first-page":"109","article-title":"Mycoses invasives en France m\u00e9tropolitaine, PMSI 2001\u20132010: incidence, l\u00e9talit\u00e9 et tendances.","volume":"12\u201313\/16 avril","author":"Bitar","year":"2013","journal-title":"BEH"},{"issue":"Suppl 4","key":"R6-20230912","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1185\/03007995.2012.761134","article-title":"Fungal diagnosis: how do we do it and can we do better?","volume":"29","author":"Perfect","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11908-014-0415-z","article-title":"Update on fungal diagnostics.","volume":"16","author":"Griffin","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"R8-20230912","first-page":"528","article-title":"Echinocandins\u2013new antifungal agents.","volume":"118","author":"Stan","year":"2014","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"R9-20230912","first-page":"27","article-title":"Micafungin: an evidence-based review of its place in therapy.","volume":"9","author":"de la Torre","year":"2014","journal-title":"Core Evid"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/INF.0b013e31821b95e2","article-title":"Echinocandins in children.","volume":"30","author":"Hoffman","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/INF.0000000000000434","article-title":"Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.","volume":"33","author":"Manzoni","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group.","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/21505594.2016.1226721","article-title":"Antifungal stewardship considerations for adults and pediatrics.","volume":"8","author":"Hamdy","year":"2017","journal-title":"Virulence"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40272-016-0211-3","article-title":"Micafungin: a review in the prophylaxis and treatment of invasive candida infections in paediatric patients.","volume":"19","author":"Scott","year":"2017","journal-title":"Paediatr Drugs"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","article-title":"The changing face of epidemiology of invasive fungal disease in Europe.","volume":"52","author":"Lass-Fl\u00f6rl","year":"2009","journal-title":"Mycoses"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/CCM.0b013e31819efac0","article-title":"Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).","volume":"37","author":"Leroy","year":"2009","journal-title":"Crit Care Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201907000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:39:00Z","timestamp":1694558340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201907000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002353","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}